0001019687-14-001280.txt : 20140407 0001019687-14-001280.hdr.sgml : 20140407 20140407102238 ACCESSION NUMBER: 0001019687-14-001280 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20140407 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140407 DATE AS OF CHANGE: 20140407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medytox Solutions, Inc. CENTRAL INDEX KEY: 0001374536 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 542156042 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54346 FILM NUMBER: 14747643 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CASINO PLAYERS, INC. DATE OF NAME CHANGE: 20060905 8-K 1 medytox_8k-040714.htm MEDYTOX SOLUTIONS, INC.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 7, 2014

Medytox Solutions, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

000-54346	54-2156042
(Commission File Number)	(I.R.S. Employer Identification No.)

400 S. Australian Avenue, Suite 800, West Palm Beach, Florida	33401
(Address of Principal Executive Offices)	(Zip Code)

(561) 855-1626

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 – Other Events

Item 8.01. Other Events

On April 7, 2014, we issued a press release announcing our results of operations for the year ended December 31, 2013, as reported in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2014.

A copy of the press release is filed as Exhibit 99.1 to this Form 8-K.

Item 9.01. Exhibits

Exhibit Number	Description
99.1	Press Release, dated April 7, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 7, 2014	MEDYTOX SOLUTIONS, INC.

	/s/ William G. Forhan
	William G. Forhan, CEO and Chairman (principal executive officer)

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release, dated April 7, 2014

EX-99.1 2 medytox_8k-ex9901.htm PRESS RELEASE

Exhibit 99.1

Medytox Solutions, Inc. Announces Results for the Year Ended December 31, 2013

Medytox Solutions, Inc. (OTC Bulletin Board: MMMS) (April 7, 2014) announced today its financial results for the year ended December 31, 2013 (the “2013 Year”). The Company reported revenues of approximately $52.5 million, which represented an increase of approximately $31.4 million, or 149%, from the approximately $21.1 million in revenues reported for the year ended December 31, 2012 (the "2012 Year"). For the 2013 Year, the Company reported income from operations of approximately $14.5 million, compared to income from operations of approximately $3.5 million for the 2012 Year.

“Our results for 2013 are a testament to the efforts of our employees and the service we provide to our customers. In particular, the increase in revenues was a direct result of increased marketing efforts for PB Laboratories and Biohealth and a full year of results for Biohealth in 2013," stated William Forhan, the Company’s Chief Executive Officer.

The Company is a holding company that owns and operates businesses in the medical services sector.

MEDYTOX SOLUTIONS, INC.

Condensed Consolidated Statements of Operations

	For the Year Ended December 31,
	2013			2012
Revenues	$	52,523,660		$	21,076,357


Total operating expenses		38,023,670			17,545,404

Income from operations		14,499,990			3,530,953

Total other income (expense)		(671,473	)		(302,598	)

Income before income taxes		13,828,517			3,228,355

Provision for income taxes		5,568,600			481,400


Net income from continuing operations		8,259,917			2,746,955

Net income (loss) from disputed activity		–			(397,918	)

Net income attributable to Medytox Solutions		8,259,917			2,349,037
Preferred stock dividends		2,601,298			50,000

Net income attributable to Medytox Solutions common shareholders	$	5,658,619		$	2,299,037

Net income per common share - Basic and diluted	$	0.19		$	0.07

Weighted average number of common shares outstanding during the period – Basic and diluted		29,654,703			30,795,073

“Forward-looking” Statements

This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995, as amended. Any such statements are made pursuant to the safe-harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, and they involve a number of risks and uncertainties that could cause actual results to differ materially from those that may be anticipated by or from the forward-looking statements. Important factors that could cause such a difference are set forth in the Company’s filings with the Securities and Exchange Commission and include, but are not limited to, the ability to consummate acquisitions and the ability to integrate such acquisitions.